Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“HER2 IHC scoring was fine-tuned for trastuzumab. ADCs, though, may require more sensitive assays. In this pilot study, we show that HER2 quantification (HS-HER2, RPPA, HER2DX) better predicts T-DXd efficacy than IHC and suggest a role for payload markers.
This is the product of 4 years of tireless work, only made possible by Sara Tolaney’s mentoring, by the tremendous biospecimens and statistical teams of Dana-Farber’s Breast Oncology Center, by amazing collaborators around the globe (including David Rimm’s lab at Yale University, Reveal Genomics. Ignite Proteomics, Duke Cancer), by the precious advice of patients advocates, and by funding kindly committed to improving the precision of ADC therapy by the Terri Brodeur Foundation, METAvivor and the Saverin family.”
Title: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Authors: Paolo Tarantino, Se-Eun Kim, Melissa E. Hughes, Ross J. Kusmick, Kalie Smith, Fara Brasó-Maristany, Nay Nwe Nyein Chan, Laia Paré Brunet, Laura Alder, Diana Garcia-Cortes, Jorge Gomez Tejeda Zanudo, Alyssa M. Pereslete, Laura Noteware, Heather Moore, Amanda E. D. Van Swearingen, Tianyu Li, Hersh Gupta, Olivia D’Amico, Alba Martini, Stefania Morganti, Jennifer Spindel, Charmaine Cook, Christine McLaughlin, Kathrin Dvir, Ana C. Garrido-Castro, Sarah Sammons, Janet Files, Kerry Sendrick, Simone Buck, Deborah Dillon, Rinath Jeselsohn, Yvonne Y. Li, Andrew D. Cherniack, Patricia LoRusso, Maryam Lustberg, Rosario Vega- León, Francisco Pardo, Justin Davis, Claudius Mueller, Brian Corgiat, Giuseppe Curigliano, Carey K. Anders, Emanuel F. Petricoin, David L. Rimm, Aleix Prat, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney
Read The Full Article
Other articles about Breast Cancer on OncoDaily.